Atlanta, GA - Southeast BIO (SEBIO) announced that it has selected ten semifinalists in its fourth annual BIO/Plan Competition. Launched in 2007, the BIO/Plan Competition is a program developed to promote the creation of new life science companies based in the Southeast. (more…)

Franklin, TN - BioMimetic Therapeutics, Inc. (NASDAQ: BMTI), announced today the closing of its previously announced underwritten public offering. Prior to closing, the underwriters exercised their option to purchase an additional approximately 642,000 shares of common stock. As a result, BioMimetic sold a total of approximately 5.64 million shares of its common stock at a price to the public of $8.50 per share. After underwriting discounts and commissions and estimated offering expenses, BioMimetic received net proceeds of approximately $45 million. (more…)

WINSTON SALEM, NC  – New research accepted by the Journal of Molecular Recognition confirms that a revolutionary technology developed at Wake Forest University will slash years off the time it takes to develop drugs – bringing vital new treatments to patients much more quickly. (more…)

ATLANTA – InVasc Therapeutics, Inc., a clinical stage biopharmaceutical company developing drugs to treat or prevent cardiometabolic disease, plans to raise $12 million, according to a regulatory filing. (more…)

Atlanta, GA – InVasc Therapeutics, Inc., a clinical stage biopharmaceutical company developing drugs to treat or prevent cardiometabolic disease has closed on $3,150,000 in its first institutional financing from Trois Investments Industriels Internationaux of Luxembourg. (more…)